The EMPOWER trial is seeking to determine which of the anti-sickness drugs, ondansetron or metoclopramide, is more effective for women who need intravenous fluid re-hydration. Women who have come to hospital after trying first line medications will be blinded to one of four arms as well as receiving IV fluid:

·         Metoclopramide + Placebo

·         Ondansatron + Placebo

·         Metoclopramide + Ondansatron

·         Placebo + Placebo

The trial will see which drug is more effective up to 10 days after starting the medication compared to placebo (dummy drug). Side effects of each drug will also be assessed

Additionally the researchers will investigate the effect NVP/HG has on the quality of life, and the symptoms of anxiety, stress and depression of sufferers.

The chief investigator is Professor Stephen Robson; Professor of Fetal Medicine & Institute of Cellular Medicine, Newcastle University and Clinical Director of the NIHR Clinical Research Network North East and North Cumbria

For more information about this trial and the rest of the research team please visit the trial website